CHF46.25: BION.SW BB Biotech AG (SIX) pre-market 18 Feb 2026 ahead of earnings

BION.SW stock trades at CHF46.25 in pre-market trade as BB Biotech AG prepares to release results on 20 Feb 2026. We focus on near-term drivers: expected earnings detail, dividend yield and portfolio revaluation. The stock is up 2.66% today on volume 52,543 shares. Investors should weigh fund-level exposure to biotech names against a current PE of 15.31 and an annual yield near 3.89%.

BION.SW stock: upcoming earnings and calendar

BB Biotech AG reports results on 20 Feb 2026 after market hours; the company listed on SIX (Switzerland) is an equity fund managed by Bellevue Asset Management. The earnings release is the immediate catalyst for price moves and could affect the fund’s NAV and portfolio weighting.

BION.SW stock financial snapshot and valuation

Price is CHF46.25, 52-week range CHF24.35–CHF49.65, market cap CHF2,550,652,628.00, and shares outstanding 55,149,246.00. Key ratios: EPS 3.02, PE 15.31, price/book 1.37, dividend per share 1.80 giving a yield near 3.89%. At a PB of 1.37 BB Biotech trades below the Healthcare sector PB average 4.22, indicating relative valuation support.

Technicals and trading context for BION.SW stock

Short-term momentum is neutral: RSI 48.72, MACD histogram negative, and ATR 1.13. Price sits close to its 50-day average CHF46.36 and above the 200-day average CHF37.76, a constructive medium-term technical setup. Liquidity is moderate: volume 52,543.00 vs average 83,305.00, relative volume 0.63.

Meyka AI rates BION.SW with a score out of 100

Meyka AI rates BION.SW with a score out of 100: 69.78 (Grade B) with a suggestion to HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects healthy free cash flow yield (17.08%), a conservative PB, and mix of portfolio risk from biotech holdings. Grades are informational and not financial advice.

Meyka AI’s forecast and price targets for BION.SW stock

Meyka AI’s forecast model projects a near-term quarterly price target of CHF51.06 and a 12-month target of CHF38.83. Versus the current CHF46.25, the quarterly target implies an upside of 10.40%, while the 12-month projection implies downside of 16.04%. Forecasts are model-based projections and not guarantees.

Risks and opportunities for BION.SW stock investors

Opportunity: BB Biotech pays a regular dividend and benefits if portfolio biotech names re-rate; dividend yield is 3.89%. Risk: as a concentrated biotech fund, stock-level volatility and pipeline binary events can move NAV materially. Operationally, cash per share is low (0.04), but working capital and tangible book provide balance sheet support.

Final Thoughts

BION.SW stock enters the earnings window at CHF46.25 with mixed signals. The near-term catalyst is the 20 Feb 2026 earnings release, which can swing NAV and share price. Fundamentals show an attractive price/book 1.37 and dividend yield 3.89%, while technicals sit near the 50-day average CHF46.36. Meyka AI’s model projects a quarterly target of CHF51.06, implying 10.40% upside, but the 12-month view at CHF38.83 implies 16.04% downside. Our read: traders will react to NAV adjustments and any changes to portfolio weighting of high-conviction biotech names. Long-term investors should weigh the fund structure, sector volatility, and dividend income. For a live view of holdings and NAV impact, see BB Biotech’s website and company profile. Forecasts are model outputs and not guarantees; use them with portfolio allocation rules and risk limits. Meyka AI is an AI-powered market analysis platform and provides data-driven context for traders and investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.